Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET

NCT00736320 is registered in ClinicalTrials.gov with University of Cologne as lead sponsor.

NCT NCT00736320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00736320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET
Lead sponsor
University of Cologne
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2009
Completion date
December 31, 2021
Enrollment
1,150 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma